DB:CDG

Stock Analysis Report

Executive Summary

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.


Snowflake Analysis

Overvalued with worrying balance sheet.


Similar Companies

Share Price & News

How has Acorda Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CDG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.6%

CDG

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-91.5%

CDG

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: CDG underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: CDG underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

CDGIndustryMarket
7 Day23.6%11.2%7.3%
30 Day-16.4%-5.3%-17.9%
90 Day-57.8%-21.9%-25.8%
1 Year-91.5%-91.5%-4.9%-5.1%-15.1%-17.7%
3 Year-96.0%-96.0%17.7%16.5%-18.7%-25.6%
5 Year-96.8%-96.8%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Acorda Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Acorda Therapeutics undervalued compared to its fair value and its price relative to the market?

0.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CDG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CDG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CDG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CDG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CDG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CDG is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Acorda Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

50.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CDG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CDG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CDG's revenue (3.4% per year) is forecast to grow slower than the German market (4.2% per year).

High Growth Revenue: CDG's revenue (3.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CDG is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Acorda Therapeutics performed over the past 5 years?

-56.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CDG is currently unprofitable.

Growing Profit Margin: CDG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CDG is unprofitable, and losses have increased over the past 5 years at a rate of -56.2% per year.

Accelerating Growth: Unable to compare CDG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: CDG has a negative Return on Equity (-87.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Acorda Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CDG's short term assets ($201.1M) exceed its short term liabilities ($86.4M).

Long Term Liabilities: CDG's short term assets ($201.1M) do not cover its long term liabilities ($402.5M).


Debt to Equity History and Analysis

Debt Level: CDG's debt to equity ratio (70.4%) is considered high.

Reducing Debt: CDG's debt to equity ratio has increased from 53.9% to 70.4% over the past 5 years.


Balance Sheet

Inventory Level: CDG has a high level of physical assets or inventory.

Debt Coverage by Assets: CDG's debt is not covered by short term assets (assets are 0.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CDG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CDG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Acorda Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CDG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CDG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CDG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CDG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CDG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Ron Cohen (63yo)

25.17s

Tenure

US$2,414,371

Compensation

Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced ...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD2.41M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ron Cohen
Founder25.17yrsUS$2.41m1.32% $593.2k
David Lawrence
CTO, Chief of Business Operations & Principal Accounting Officer6.42yrsUS$972.60k0.027% $12.2k
Burkhard Blank
Chief Medical Officer and Head of R&D4.17yrsUS$1.34m0.086% $38.8k
Jane Wasman
Consultant0.25yrUS$1.26m0.24% $110.1k
Felicia Vonella
Vice President of Investor Relationsno datano datano data
Andrew Mayer
Senior VP0.33yrno datano data
Tierney Saccavino
Executive Vice President of Corporate Communications5.17yrsno datano data
Denise Duca
Executive Vice President of Human Resources5.17yrsno datano data
Andrew Blight
Chief Scientific Officer Emeritus20.17yrsUS$1.48mno data
Lauren Sabella
Chief Commercial Officer10.17yrsUS$1.49m0.026% $11.8k

5.2yrs

Average Tenure

63yo

Average Age

Experienced Management: CDG's management team is seasoned and experienced (5.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ron Cohen
Founder25.17yrsUS$2.41m1.32% $593.2k
Lorin Randall
Independent Director14.17yrsUS$290.37kno data
Steven Rauscher
Independent Director15yrsUS$292.37kno data
Sandra Panem
Independent Director22.17yrsUS$294.37k0.0061% $2.7k
Mark Tuszynski
Member of Scientific Advisory Boardno datano datano data
Melitta Schachner
Member of Scientific Advisory Boardno datano datano data
Patrick Tresco
Member of Scientific Advisory Boardno datano datano data
Stephen Waxman
Member of Scientific Advisory Boardno datano datano data
Mary Bunge
Member of Scientific Advisory Boardno datano datano data
John Kelley
Non-executive Chairman0.33yrUS$297.37kno data

15.0yrs

Average Tenure

65yo

Average Age

Experienced Board: CDG's board of directors are seasoned and experienced ( 15 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Acorda Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acorda Therapeutics, Inc.
  • Ticker: CDG
  • Exchange: DB
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$49.917m
  • Listing Market Cap: US$45.020m
  • Shares outstanding: 48.00m
  • Website: https://www.acorda.com

Number of Employees


Location

  • Acorda Therapeutics, Inc.
  • 420 Saw Mill River Road
  • Ardsley
  • New York
  • 10502
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CDGDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2006
ACORNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2006
CDGBRSE (Berne Stock Exchange)YesCommon StockCHCHFFeb 2006

Biography

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson’s disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson’s disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 21:27
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.